Royalty Pharma's total assets for Q3 2025 were $19.35B, an increase of 5.59% from the previous quarter. RPRX total liabilities were $9.73B for the fiscal quarter, a 10.28% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.